Intranasal Dendrimeric Aβ1–15 Boosts Immune Response in Alzheimer's Mice
Author Information
Author(s): Seabrook Timothy J, Jiang Liying, Thomas Katelyn, Lemere Cynthia A
Primary Institution: Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School
Hypothesis
Can intranasal dendrimeric Aβ1–15 effectively boost the immune response in APP-tg mice after priming with Aβ1–40/42?
Conclusion
Priming with Aβ1–40/42 followed by boosting with dendrimeric Aβ1–15 led to a strong immune response and reduced Aβ plaque burden in APP-tg mice.
Supporting Evidence
- J20 APP-tg mice boosted with dendrimeric Aβ1–15 produced high levels of anti-Aβ antibodies.
- A significant reduction in Aβ plaque burden was observed in treated mice.
- Wildtype mice produced higher amounts of anti-Aβ antibodies compared to APP-tg mice.
Takeaway
The study shows that a special vaccine can help mice fight Alzheimer's by making their immune system produce antibodies against a harmful protein.
Methodology
Mice were primed with Aβ1–40/42 and boosted intranasally with either dendrimeric Aβ1–15 or Aβ1–15 peptide, followed by analysis of immune response and Aβ levels.
Potential Biases
Potential bias due to the specific genetic background of the mice used.
Limitations
The study primarily involved mouse models, which may not fully replicate human responses.
Participant Demographics
J20 APP-tg mice and wildtype littermates.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website